3 hours ago
7
Key Highlights
- QURE stock decreased 0.90% to reach $48.60 following the offering announcement.
- The company issued 4.95 million ordinary shares priced at $45.50 per share.
- Gross proceeds could total approximately $225 million, excluding underwriting fees.
- A greenshoe option permits underwriters to acquire an additional 741,758 shares.
- The capital injection enhances liquidity while introducing shareholder dilution.
Shares of uniQure N.V. (QURE) declined 0.90% to settle at $48.60 following the announcement of a substantial equity offering priced below current trading levels. Throughout the trading day, QURE experienced volatility, momentarily reaching highs above $49.90 before retreating. While the capital raise bolsters the company’s financial reserves, investors expressed concern over the dilutive impact of newly issued equity.
Public Offering Priced at Discount to Current Market
uniQure established a price of $45.50 for 4,945,055 ordinary shares in its underwritten public offering. This pricing represents a discount compared to QURE’s prevailing market value of $48.60. The below-market pricing triggered selling pressure as investors weighed the dilutive consequences of the share issuance.
The biotech company anticipates receiving roughly $225 million in gross proceeds before deducting underwriting fees, commissions, and related transaction expenses. All shares in the offering will be sold by uniQure itself, with the company retaining all proceeds. Specific net proceeds figures after accounting for transaction costs have not been disclosed.
The offering is scheduled to conclude on or near June 25, pending satisfaction of customary closing conditions. The transaction’s finalization depends on completing routine legal and administrative requirements. This accelerated timeline enables uniQure to rapidly access the raised capital following the pricing announcement.
Greenshoe Provision May Expand Total Capital Raised
uniQure extended to underwriters a standard 30-day over-allotment option for an additional 741,758 ordinary shares. Investment banks may exercise this option at the same $45.50 price, after deducting underwriting discounts and commissions. Full exercise would contribute approximately $33.8 million in additional gross proceeds.
Consequently, maximum gross proceeds could reach roughly $258.8 million if underwriters fully utilize this option. Without the over-allotment, the base offering generates approximately $225 million before expenses. Exercising the greenshoe option would amplify dilution by increasing the total number of shares entering the market.
The syndicate of underwriters includes Leerink Partners, Stifel, Guggenheim Securities, and RBC Capital Markets as joint bookrunning managers. H.C. Wainwright serves as the lead manager for the transaction. These financial institutions will orchestrate share distribution and oversee the sale pursuant to underwriting agreements.
Capital Raise Supports Gene Therapy Development Initiatives
uniQure specializes in developing gene therapy treatments for severe medical conditions with few existing therapeutic options. The company’s pipeline encompasses experimental therapies addressing Huntington’s disease and additional serious neurological disorders. Advancing clinical trials and navigating regulatory pathways necessitate substantial ongoing capital investment.
The biotech firm recently disclosed favorable regulatory developments concerning its primary Huntington’s disease gene therapy candidate. This announcement triggered a substantial rally in QURE shares prior to the equity offering disclosure. The fundraising enables uniQure to bolster its balance sheet following the recent stock price appreciation.
uniQure utilized an automatically effective shelf registration statement filed in January 2025 to facilitate this offering. A preliminary prospectus supplement was submitted to the SEC on June 22, 2026. The final prospectus supplement detailing complete offering terms will be filed subsequently.
QURE Shares Retreat Following Intraday Volatility
QURE stock exhibited significant intraday price fluctuations as traders digested the discounted offering price. Shares temporarily surpassed $49.90 before losing traction and reversing course. The stock ultimately settled around $48.60, marking a 0.90% decrease for the session.
Despite the daily decline, QURE continued trading $3.10 above the offering price. This premium reflected ongoing investor enthusiasm stemming from uniQure’s recent clinical and regulatory achievements. However, the introduction of new share supply constrained upward momentum during the trading session.
The financing strengthens uniQure’s cash resources to fund operations and accelerate pipeline development activities. Simultaneously, existing shareholders face dilution from the issuance of nearly five million new ordinary shares. The interplay between enhanced financial flexibility and increased share count influenced QURE’s recent trading behavior.
English (US) ·